Results 11 to 20 of about 5,304 (170)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

open access: yesHemaSphere, 2022
Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia (CLL). ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator’s choice of idelalisib plus rituximab (IdR) or bendamustine plus ...
Paolo Ghia   +17 more
doaj   +3 more sources

Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database

open access: yesZhongliu Fangzhi Yanjiu, 2022
Objective To explore the potential adverse reactions of acalabrutinib by mining and analyzing the pharmacovigilance signal of acalabrutinib, to provide a reference for clinically safe and rational drug use.
LIANG Cuilyu, ZHANG Yin, CHEN Qiying
doaj   +2 more sources

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia [PDF]

open access: yesHaematologica, 2021
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients.
Kerry A. Rogers   +13 more
doaj   +2 more sources

The role of acalabrutinib in adults with chronic lymphocytic leukemia [PDF]

open access: yesTherapeutic Advances in Hematology, 2021
The treatment landscape of chronic lymphocytic leukemia (CLL) has significantly changed in the past decade. This paradigm shift is due to the introduction of novel agents to the field. The two major classes of drugs that have contributed to this dramatic
Bita Fakhri, Charalambos Andreadis
doaj   +2 more sources

Acalabrutinib‐related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta‐analysis of randomised controlled trials (RCTs)

open access: yeseJHaem, 2021
Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks
Thura W. Htut   +2 more
doaj   +2 more sources

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. [PDF]

open access: yesPLoS ONE, 2016
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib.
Bonnie K Harrington   +18 more
doaj   +2 more sources

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions [PDF]

open access: yesHaematologica, 2019
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two ...
Jennifer Series   +6 more
doaj   +2 more sources

Acalabrutinib Approved for MCL [PDF]

open access: yesCancer Discovery, 2018
Abstract The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the only BTK inhibitor on the market.
openaire   +3 more sources

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor [PDF]

open access: yesJournal of Hematology & Oncology, 2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic ...
Jingjing Wu, Mingzhi Zhang, Delong Liu
doaj   +2 more sources

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI [PDF]

open access: yesHaematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson   +14 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy